Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Foscarbidopa→

Foscarbidopa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1907685-81-7
Molecular formula
C10H15N2O7P
Molecular weight
306.21 g/mol
Drug class
Carbidopa prodrugpyridoxine-independent peripheral dopa-decarboxylase inhibitor component of VYALEV
Mechanism of action
Foscarbidopa is a phosphate prodrug converted to carbidopa, which inhibits peripheral aromatic L-amino-acid decarboxylase and reduces peripheral conversion of levodopa to dopamine, increasing levodopa availability to the brain. It is used as part of the fixed foscarbidopa/foslevodopa combination.
Indications / reported uses
  • Component of the fixed combination VYALEV (foscarbidopa/foslevodopa) for treatment of motor fluctuations in adults with advanced Parkinson disease; not a stand-alone approved indication

Sources: US DailyMed — VYALEV prescribing information · FDA product information — VYALEV · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Foscarbidopa Environmental Risk Assessment (ERA) (the Foscarbidopa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.